New Treatment Options for Breast Cancer

Size: px
Start display at page:

Download "New Treatment Options for Breast Cancer"

Transcription

1 New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of Iowa College of Pharmacy

2 Disclosures Brandon Vakiner reports no relevant financial disclosures

3 Objectives Discuss recently published literature regarding breast cancer (BC) treatment Review recently FDA-approved breast cancer treatments Name Mechanism of Action (MOA) Adverse Effects Place in Therapy Review relevant studies

4 Everolimus (Afinitor): BOLERO pts randomized in a 2:1 ratio to everolimus 10 mg/day plus exemestane 25 mg/day vs. exemestane plus placebo Hormone-receptor positive, HER-2 negative advanced breast cancer Recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both) Primary end point: progression-free survival (PFS) based on radiographic studies Secondary: overall survival (OS), overall response rate Baselga J, et al. NEJM. 2012;366:520-9

5 BOLERO-2 Results Median PFS by investigator assessment 7.8 months for patients receiving everolimus 3.2 months for patients receiving placebo [HR 0.45 (95 percent CI: ), p < ] Objective response rates 12.6 percent in patients receiving everolimus 1.7 percent in patients receiving placebo Interim analysis of OS conducted at 46% of expected events was not statistically significant [HR=0.77 (95 percent CI: 0.57, 1.04)] Final analysis of OS is expected to occur in June 2014

6 Tamoxifen: ATLAS & attom ATLAS Adjuvant Tamoxifen: Longer Against Shorter From , randomized 6846 women with ER+ disease already taking tamoxifen to stop after 5 years or continue to 10 years women were evaluated for safety evaluation attom adjuvant Tamoxifen Treatment offers more? From , 6,953 women with ER+ (n=2755), or ER untested (4198, estimated 80% ER+ if status known) invasive BC from 176 UK centers randomized to stop tamoxifen after 5 years of or continue to year 10 Davies C, et al. Lancet. 2013;381: Gray RJ, et al. J Clin Oncol (Meeting Abstracts). 2013; 31(18): suppl 5

7 ATLAS Continuing reduced: Risk for BC recurrence (617 vs 711; P =.002), BC mortality (331 vs 397 deaths; P =.01) Overall mortality (639 vs 722 deaths; P =.01) Continuing increased risk for endometrial CA (relative risk [RR], 1.74) & for pulmonary embolism (RR, 1.87). attom Continuing reduced: BC recurrences (28% vs 32%; P =.003) BC mortality (392 vs 443 deaths after recurrence; 21% vs 24%; P =.06) Non-BC mortality was little affected (457 vs 467 deaths, rate ratio 0.94 [ ]) Endometrial cancers RR=2.20 ( , p<0.0001)

8 The HER Family Accessed 10/7/13

9 HER2 & HER3 HER2 gene is amplified & overexpressed in about 25% of BC, leading to more aggressive disease HER2 not only important in development of BC but drives progression & metastasis in its advanced stages HER3 is frequently overexpressed in BC with HER2 overexpression, and increased expression of HER3 synergistically increases transforming potency of HER2 HER2 HER3 signaling complex is highly effective in activating the PI3K/Akt pathway Hsieh AC, Moasser MM. Br J Cancer. 2007;97:

10 Pertuzumab injection (Perjeta, Genentech) Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab Combined with trastuzumab & docetaxel for treatment of HER2-positive (HER2+) metastatic breast cancer who haven t received prior anti-her2 therapy or chemotherapy for metastatic disease Initial dose: 840 mg over 60 minutes Maintenance: 420 mg over minutes every 3 weeks Mix & Monitoring are the same as trastuzumab Perjeta IV injection [package insert]. South San Francisco, CA: Genentech Inc.; June 2012

11 Mechanism of Action Accessed 3/11/13.

12 Randomized 808 patients with HER2+ metastatic BC to firstline treatment with: Placebo + trastuzumab + docetaxel (control group) Pertuzumab + trastuzumab + docetaxel (pertuzumab group) Primary end pt: PFS (independently assessed) Secondary end pts: OS, PFS (investigator assessed), objective response rate, & safety

13 Pertuzumab: CLEOPATRA Increased median PFS 12.4 months docetaxel & trastuzumab 18.5 months docetaxel, trastuzumab and pertuzumab Toxicity greater in pertuzumab group: Any Grade: diarrhea, rash, dry skin, mucositis, febrile neutropenia Grade 3 or higher: febrile neutropenia & diarrhea Combination showed no increased rates of cardiac dysfunction Strong trend for increased OS Baselga J, et al. NEJM. 2012;366:109-19

14 In the intention-to-treat population, 267 patients died by data cutoff (05/14/12) 154 (38%) of 406 in the placebo group 113 (28%) of 402 in the pertuzumab group Median OS was 37.6 months (95% CI 34 3 NE [not estimable]) in the placebo group but had not been reached (95% CI 42 4 NE) in the pertuzumab group (hazard ratio 0 66, 95% CI ; p=0 0008)

15 FDA Approves Pertuzumab for Neoadjuvant Breast Cancer On Sept. 30, 2013 the FDA granted accelerated approval to pertuzumab in combination with trastuzumab & docetaxel for the neoadjuvant treatment of patients with HER2+, locally advanced, inflammatory, or early stage BC as part of a complete treatment regimen for early breast cancer Is this setting a new precedent? Accessed 10/01/13

16 Neoadjuvant Pertuzumab Should be administered every 3 weeks for 3 to 6 cycles as part of one of the following treatment regimens for early breast cancer: Four preoperative cycles of pertuzumab in combination with trastuzumab and docetaxel followed by 3 postoperative cycles of FEC Three preoperative cycles of FEC alone followed by 3 preoperative cycles of pertuzumab in combination with docetaxel and trastuzumab Six preoperative cycles of pertuzumab in combination with docetaxel, carboplatin and trastuzumab (TCH) Following surgery, patients should continue to receive trastuzumab to complete 1 year of treatment Insufficient evidence to recommend: continued use of pertuzumab for greater than 6 cycles for early breast cancer concomitant administration of an anthracycline with pertuzumab, and there are no safety data to support sequential use of doxorubicin with pertuzumab

17 Ado-Trastuzumab Emtansine IV (Kadcyla, Genentech) First antibody-drug conjugate (ADC) for the treatment of HER2+ tumors HER2-targeted antitumor properties of trastuzumab Cytotoxic activity of the microtubule-inhibitory agent DM1 Single agent for HER2+, metastatic BC who have received trastuzumab and a taxane (separate or in combo) Received prior therapy for metastatic disease Developed recurrence during or within six months of completing adjuvant therapy Kadcyla IV injection [package insert]. South San Francisco, CA: Genentech Inc.; Feb 2013

18 Accessed 9/12/13

19 Ado-Trastuzumab Emtansine Dose: 3.6 mg/kg diluted it in 250 ml NS IV every 3 weeks DO NOT administer at doses greater than 3.6 mg/kg. Do not substitute for or with trastuzumab Infuse first dose over 90 minutes, subsequent doses over 30 min Administer with a 0.22 micron in-line non-protein adsorptive polyethersulfone (PES) filter Monitor for at least 30 minutes after infusion Monitoring similar to taxanes and trastuzumab Kadcyla IV injection [package insert]. South San Francisco, CA: Genentech Inc.; Feb 2013

20 Randomized 991 patients with HER2+ advanced BC, previously treated with trastuzumab & a taxane, to T-DM1 or lapatinib plus capecitabine Primary end points: PFS (independent review), OS, & safety Secondary end points: PFS (investigator-assessed), objective response rate, & time to symptom progression

21 EMILIA: Progression-Free Survival Verma S, et al. NEJM. 2012; 367:

22 EMILIA: Overall Survival Verma S, et al. NEJM. 2012; 367:

23 Toxicity Most common (> 25%): fatigue, nausea, musculoskeletal pain, thrombocytopenia, headache, increased transaminases, and constipation Most common (> 2%) Grade 3-4: thrombocytopenia*, increased transaminases*, anemia, hypokalemia, peripheral neuropathy and fatigue Serious hepatobiliary disorders have been reported Other significant adverse reactions include left ventricular dysfunction, interstitial lung disease, & infusion-associated reactions *most common leading to withdrawal from study Kadcyla IV injection [package insert]. South San Francisco, CA: Genentech Inc.; Feb 2013 Verma S, et al. NEJM. 2012; 367:

24 Toxicity Severity Recommendation Thrombocytopenia Grade 3 (Platelets [PLT] 25K to < 50K) Do not administer until PLT count recovers to Grade 1 (>75K), then treat at same dose level Grade 4 (PLT < 25K) Do not administer until PLT count recovers to Grade 1, then reduce one dose level Increased AST/ALT Grade 2 (>2.5 to 5 x Upper Limit Normal) Treat at same dose level Grade 3 (> 5 to 20 x ULN) Grade 4 (>20 x ULN) Do not administer until AST/ALT recovers to Grade 2, then reduce one dose level Permanently discontinue Hyperbilirubinemia Grade 2 (>1.5 to 3 x ULN) Do not administer until total bilirubin recovers to Grade 1, then treat at same dose level Grade 3 (>3 to 10 x ULN) Grade 4 (> 10 x ULN) Do not administer until total bilirubin recovers to Grade 1, then reduce one dose level Permanently discontinue Left Ventricular Dysfunction (Left ventricular ejection fraction [LVEF]) LVEF > 45% LVEF 40% to 45% and decrease is < 10% points from baseline LVEF 40% to 45% and decrease is 10% points from baseline LVEF < 40% Symptomatic CHF Continue treatment Continue treatment & repeat LVEF assessment within 3 weeks Do not administer. Repeat within 3 weeks & if LVEF has not recovered to within 10% points from baseline, Discontinue Do not administer. Repeat within 3 weeks & if LVEF < 40% is confirmed, Discontinue Discontinue

What s New With HER2?

What s New With HER2? What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:

More information

CLINICAL POLICY Department: Medical Management Document Name: HER2 Breast Cancer Treatments

CLINICAL POLICY Department: Medical Management Document Name: HER2 Breast Cancer Treatments Page: 1 of 11 Specialist Review: Revised: 06/13 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness

More information

What is the optimal sequence of anti-her2 therapy in metastatic breast cancer?

What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival

More information

5.04.20. Perjeta. Perjeta (pertuzumab) Description

5.04.20. Perjeta. Perjeta (pertuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Management of Locally Advanced and Metastatic HER2-Positive Breast Cancer

Management of Locally Advanced and Metastatic HER2-Positive Breast Cancer Management of Locally Advanced and Metastatic HER2-Positive Breast Cancer Pretest Question #1 Which of the following is an antibody-drug conjugate indicated for use in HER2-positive metastatic breast cancer?

More information

Miquel Àngel Seguí Palmer

Miquel Àngel Seguí Palmer Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with

More information

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab. Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

A Phase 1 Study of MM-302, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC)

A Phase 1 Study of MM-302, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC) A Phase 1 Study of MM-32, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC) P LoRusso 1, I Krop 2, K Miller 3, C Ma 4, BA Siegel 4, AF Shields

More information

FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer

FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer Media Release Basel, 2 July, 2013 FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer Application follows proposed new FDA pathway designed

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

New Approval Mechanism for Breast Cancer using pathologic Complete Response

New Approval Mechanism for Breast Cancer using pathologic Complete Response New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine

More information

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University

Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University Assoc. Editor ASCO University and JGO Progress Against

More information

Strength of Study End Point(s): Progression-free survival

Strength of Study End Point(s): Progression-free survival AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and

More information

Seconda linea di trattamento

Seconda linea di trattamento XVIII Congresso Nazionale CIPOMO Roma, Giugno 2013 Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Seconda linea di trattamento Giorgio

More information

HER2 positive breast cancer. Rachel Dear MBBS PhD Staff specialist SVH/TKCC 18 March 2016

HER2 positive breast cancer. Rachel Dear MBBS PhD Staff specialist SVH/TKCC 18 March 2016 HER2 positive breast cancer Rachel Dear MBBS PhD Staff specialist SVH/TKCC 18 March 2016 Matching breast cancer types to treatment Triple negative Basal Stem cell Chemotherapy PARP inhibitors Her 2 pos

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic

More information

DRUG NAME: Pertuzumab

DRUG NAME: Pertuzumab DRUG NAME: Pertuzumab SYNONYM(S): COMMON TRADE NAME(S): PERJETA CLASSIFICATION: monoclonal antibody Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM

More information

Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania

Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal

More information

Optimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice

Optimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice Optimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice Learning Objectives Discuss recent clinical trials showing survival advantages in the treatment of

More information

12.5 VI.2 ELEMENTS FOR A PUBLIC SUMMARY

12.5 VI.2 ELEMENTS FOR A PUBLIC SUMMARY 12.5 VI.2 ELEMENTS FOR A PUBLIC SUMMARY 12.5.1 VI.2.1 Overview of disease epidemiology Breast cancer affects 10 12% of women globally, and is more common among older people. Some cancer cells have proteins

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Breast Cancer: Background

Breast Cancer: Background Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of August 2014. All materials contained herein reflect the views of the faculty, and not those

More information

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer a systematic review

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer a systematic review Mendes et al. Breast Cancer Research (2015) 17:140 DOI 10.1186/s13058-015-0648-2 RESEARCH ARTICLE The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Horizon Scanning in Oncology

Horizon Scanning in Oncology Horizon Scanning in Oncology Pertuzumab (Omnitarg/Perjeta ) for the first-line therapy of metastatic HER2 positive breast cancer DSD: Horizon Scanning in Oncology Nr. 31 ISSN online 2076-5940 Horizon

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

New Agents as Options in the Treatment of Breast Cancer in 2012 2013. Realities and Possibilities

New Agents as Options in the Treatment of Breast Cancer in 2012 2013. Realities and Possibilities New Agents as Options in the Treatment of Breast Cancer in 2012 2013. Realities and Possibilities Peter M. Ravdin, MD, PhD UT Health Science Center San Antonio San Antonio, TX 2012 2013 New Options for

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Breast Cancer Educational Program. June 5-6, 2015

Breast Cancer Educational Program. June 5-6, 2015 Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Cellular, Molecular, and Biochemical Targets in Breast Cancer

Cellular, Molecular, and Biochemical Targets in Breast Cancer Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm

More information

Molecular Classification of Breast Cancer: The Paradigm Shift in the Treatment of Breast Cancer

Molecular Classification of Breast Cancer: The Paradigm Shift in the Treatment of Breast Cancer Molecular Classification of Breast Cancer: The Paradigm Shift in the Treatment of Breast Cancer Rena D. Callahan, MD Assistant Clinical Professor of Medicine Breast Cancer Program Department of Medicine,

More information

IBRANCE is not approved for any indication in any market outside the U.S.

IBRANCE is not approved for any indication in any market outside the U.S. IBRANCE (palbociclib) Fact Sheet IBRANCE (palbociclib) is an oral inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal

More information

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer The new england journal of medicine original article Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D., Jungsil

More information

METASTATIC BREAST CANCER

METASTATIC BREAST CANCER METASTATIC BREAST CANCER Executive Summary Metastatic breast cancer is defined as disease beyond the breast and regional lymph nodes. Although metastatic breast cancer is generally incurable, patients

More information

DRUG NAME: Trastuzumab emtansine

DRUG NAME: Trastuzumab emtansine DRUG NAME: Trastuzumab emtansine SYNONYM(S): T-DM1, trastuzumab-dm1, trastuzumab-mcc-dm1, ado-trastuzumab emtansine 1 COMMON TRADE NAME(S): KADCYLA CLASSIFICATION: miscellaneous Special pediatric considerations

More information

The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment

The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment Ahmad Awada, MD, PhD Head of Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

HER2-positive Metastatic Breast Cancer: New Agents on the Horizon

HER2-positive Metastatic Breast Cancer: New Agents on the Horizon Hong Kong J Radiol. 2012;15(Suppl):S51-6 REVIEW ARTICLE HER2-positive Metastatic Breast Cancer: New Agents on the Horizon W Yeo Department of Clinical Oncology, The Chinese University of Hong Kong, Prince

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market

More information

Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles

Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor

More information

ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico

ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213

More information

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

Curr Oncol, Vol. 22, pp. S19-28; doi: http://dx.doi.org/10.3747/co.22.2363 TARGETED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER REVIEW ARTICLE

Curr Oncol, Vol. 22, pp. S19-28; doi: http://dx.doi.org/10.3747/co.22.2363 TARGETED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER REVIEW ARTICLE Curr Oncol, Vol. 22, pp. S19-28; doi: http://dx.doi.org/10.3747/co.22.2363 TARGETED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER REVIEW ARTICLE Targeted therapy in her2-positive metastatic breast

More information

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol FEC-DH in the adjuvant treatment of Breast Cancer (BRWOS- 031/1) Indication Adjuvant chemotherapy for HER2+ve Early Breast Cancer Eligibility

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

La Terapia Personalizzata in Oncologia

La Terapia Personalizzata in Oncologia AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA La Terapia Personalizzata in Oncologia Roma, 25-26 Ottobre 2011 Stato dell arte e prospettive della Target Therapy nei tumori mammari PierFranco Conte Department

More information

cure to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More

cure to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More A Patient s Guide to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More cure C a n c e r U p d a t e s, R e s e a

More information

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer Network Chemotherapy Protocols Breast Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced

More information

Clinical Spotlight in Breast Cancer

Clinical Spotlight in Breast Cancer 2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared

More information

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen. Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

Adjuvant Therapy with Trastuzumab

Adjuvant Therapy with Trastuzumab Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products

More information

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast

More information

San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 10 14, 2013

San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 10 14, 2013 Final Analysis of a Phase II, 3-Arm, Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by 6 cycles of Docetaxel and Carboplatin with Trastuzumab

More information

Metastatic Breast Cancer: where are we and where are we going?

Metastatic Breast Cancer: where are we and where are we going? Metastatic Breast Cancer: where are we and where are we going? Dr. Stefania Redana Clinical Research Fellow The Royal Marsden Hospital Thursday 5 th November 2015 Outline Overview on Breast Cancer Statistics

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

REF/2011/06/002450 CTRI Website URL - http://ctri.nic.in

REF/2011/06/002450 CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Thu, 14 Jul 2016 07:52:01 GMT) CTRI Number Last Modified On 08/07/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

SAMO FoROMe Post-ESMO 2013 Breast Cancer

SAMO FoROMe Post-ESMO 2013 Breast Cancer SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news

More information

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment.

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. 1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300

More information

Breast Cancer Care & Research

Breast Cancer Care & Research Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female

More information

London Cancer New Drugs Group APC/DTC Briefing

London Cancer New Drugs Group APC/DTC Briefing London Cancer New Drugs Group APC/DTC Briefing Continued use of trastuzumab following disease progression in metastatic breast cancer Contents Summary 1 Background 2 Adverse events/safety issues Health

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.

More information

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER Definitions: NACT is recommended initial treatment for inflammatory breast cancer and inoperable

More information

HER2 Testing in Breast Cancer

HER2 Testing in Breast Cancer HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

I. THE IMPORTANCE OF HER2 IN BREAST CANCER

I. THE IMPORTANCE OF HER2 IN BREAST CANCER I. THE IMPORTANCE OF HER2 IN BREAST CANCER The human epidermal growth factor receptors (HER), also known as ERBB receptors, are a family of signal transduction proteins. There are 4 family members in humans

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Treatment of Breast Cancer after Surgery. What Primary Care Providers Need to Know

Treatment of Breast Cancer after Surgery. What Primary Care Providers Need to Know Treatment of Breast Cancer after Surgery What Primary Care Providers Need to Know Disclosure of Potential for Conflict of Interest Dr. Chris Ogaranko Treatment of Breast Cancer after Surgery FINANCIAL

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

Metastatic Breast Cancer: The Art and Science of Systemic Therapy. Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba

Metastatic Breast Cancer: The Art and Science of Systemic Therapy. Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba Metastatic Breast Cancer: The Art and Science of Systemic Therapy Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba Presenter Disclosure Faculty: Dr. Vallerie Gordon Relationships with commercial

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI

NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de

More information